iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023. The source filing is a fiscal-year 2023 Form 10-K, not a standalone 2022 fourth-quarter filing.
Business Context
iBio is a preclinical biotechnology company focused on AI-enabled precision antibody discovery and development. During fiscal 2023, the Company acquired substantially all of RubrYc Therapeutics’ assets, including its AI drug-discovery platform and antibody programs, and pivoted away from its contract development and manufacturing organization (CDMO) business.
- Core technologies include epitope-steering AI, StableHu antibody optimization, mammalian display, and the EngageTx CD3 T-cell engager platform.
- The pipeline is primarily focused on immuno-oncology, with additional programs in autoimmune disease and other therapeutic areas.
- The Company completed a San Diego R&D laboratory and had 23 iBio employees and 3 employees supporting the Bryan, Texas facility at June 30, 2023.
Financial Performance and Liquidity
| Metric | Fiscal 2023 | Fiscal 2022 |
|---|---|---|
| Continuing-operations revenue | $0 | $1.884 million |
| Research and development expense | $10.327 million | $9.827 million |
| General and administrative expense | $19.016 million | $21.754 million |
| Total operating expenses | $29.343 million | $31.581 million |
| Loss from continuing operations | $29.311 million | $29.600 million |
| Loss from discontinued operations | $35.699 million | $20.791 million |
| Net loss attributable to stockholders | $65.010 million | $50.391 million |
| Net loss per share | $5.31 | $5.78 |
| Cash used in operating activities | $30.436 million | $37.480 million |
| Cash, cash equivalents and restricted cash | $7.579 million | $28.672 million |
| Accumulated deficit | $288.940 million | $223.930 million |
Continuing-operations revenue fell to zero because the ongoing business is preclinical and the former CDMO operations were classified as discontinued operations. Fiscal 2023 R&D expense increased 5%, primarily from internal pipeline work and the San Diego facility. G&A expense declined 13% due largely to lower impairment, legal, consulting, and travel costs.
The Company reported no meaningful operating margin because it has no commercial products and continues to incur substantial operating losses. Fiscal 2023 investing cash flow was positive $7.009 million, primarily from sales and redemptions of debt securities and fixed assets. Financing cash flow was positive $2.301 million, including equity proceeds, partially offset by $9.318 million of term-loan repayments.
Material Changes Versus the Prior Period
- Completed the RubrYc asset acquisition in September 2022 for approximately $1.342 million of allocated consideration, including stock, and obtained rights to multiple antibody programs and the AI platform.
- Ceased CDMO operations, reduced the workforce by approximately 60%, and classified the CDMO business as discontinued operations.
- Recorded approximately $17.9 million of fixed-asset impairments, $4.9 million of inventory reserves, and approximately $7.5 million of personnel-related and other restructuring costs in discontinued operations.
- Loss from discontinued operations increased 72% to $35.7 million, driving the increase in total net loss.
- Issued common stock through at-the-market offerings and a December 2022 underwritten offering; fiscal 2023 equity proceeds totaled approximately $11.487 million before certain related effects.
- Common shares outstanding increased to 20.310 million at June 30, 2023 from 8.727 million at June 30, 2022, on a reverse-split-adjusted basis.
- Completed a one-for-25 reverse stock split effective October 7, 2022.
- Term-loan principal declined to approximately $13.057 million before deferred financing costs at June 30, 2023 from $22.375 million at June 30, 2022.
Pipeline, Guidance and Management Commentary
- IBIO-101 advanced to the IND-enabling stage. Management anticipates filing an IND during calendar year 2025, subject to successful development and regulatory preparation.
- The TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and PD-1 agonist programs remain preclinical or late-discovery programs.
- Management expects fiscal 2024 R&D expense to be approximately comparable to fiscal 2023 and expects G&A expense to continue decreasing.
- The Company entered into a research collaboration with NIAID to evaluate its epitope-steering platform for a Lassa fever vaccine.
- Management is evaluating additional capital, asset sales, licensing, collaborations, grants, and further cost reductions to extend its cash runway.
Debt, Contingencies and Going-Concern Risks
The audited financial statements include a going-concern emphasis. Management and the auditor concluded that recurring losses, negative operating cash flow, limited liquidity, and dependence on additional financing create substantial doubt about the Company’s ability to continue as a going concern for the next 12 months after issuance of the financial statements.
- Cash, cash equivalents and restricted cash of approximately $7.6 million at June 30, 2023 was not expected to fund operations through the second quarter of fiscal 2024 without additional cost reductions, financing, asset sales, or other liquidity measures.
- The Woodforest term loan had an outstanding balance of approximately $12.7 million as of September 26, 2023 and, after subsequent amendments, matured no later than December 31, 2023.
- The credit agreement required at least $1.0 million of unrestricted cash and restricted additional indebtedness, asset sales, and other corporate actions.
- In September 2023, iBio CDMO agreed to sell the Bryan facility for $17.25 million, with proceeds intended to repay the Woodforest term loan. Closing was subject to due diligence, Texas A&M approval, title, and other conditions; the filing states that completion was not assured.
- The Company disclosed a prior liquidity-covenant breach in January 2023, followed by multiple amendments to the credit agreement.
- Subsequent to year-end, the Company entered into a Lincoln Park equity purchase agreement for up to $10 million, subject to conditions and exchange-cap limitations, and sold additional shares through Lincoln Park and Cantor Fitzgerald.
- The Company has no approved commercial products, no significant recurring revenue source, and expects continuing losses and negative cash flows.
Unusual Items and Other Matters
- The Company terminated its University of Pittsburgh license related to the IBIO-100 antifibrotic program and discontinued that program.
- Approximately $565,000 of intellectual property, patents, and licenses that would no longer be used were impaired.
- The Company’s indefinite-lived IBIO-101 license, carried at approximately $5.0 million, passed its fiscal 2023 impairment test, but management identified it as subject to future impairment risk.
- A material weakness related to stock-based compensation accounting identified during fiscal 2023 was reported as remediated at June 30, 2023. Management concluded that internal controls over financial reporting were effective, but the auditor did not provide an internal-control attestation because iBio is a smaller reporting company.
- The Company has approximately $202.1 million of federal net operating loss carryforwards and approximately $1.76 million of R&D tax credit carryforwards, all subject to valuation allowances and possible Section 382 limitations.
Investor Verification Checklist
- Verify whether the Bryan facility sale closed, the actual net proceeds received, and whether the Woodforest term loan was fully repaid or otherwise refinanced.
- Reconcile post-year-end equity issuances, warrant repricing and exercises, commitment shares, and the resulting fully diluted share count.
- Assess the Company’s current cash runway, quarterly cash burn, restricted cash, and compliance with debt covenants.
- Confirm progress toward IBIO-101 IND-enabling activities and the likelihood and timing of the targeted 2025 IND filing.
- Evaluate whether preclinical efficacy claims for IBIO-101 and other programs have been independently validated and translated into IND-quality data.
- Review potential impairment of the IBIO-101 license and other intellectual property if financing, pipeline priorities, stock price, or development plans deteriorate.
- Monitor whether the Company can generate collaboration, licensing, grant, or product revenue, since fiscal 2023 continuing-operations revenue was zero.